Chimeric Antigen Receptors Targeting CD79B and CD19 for Cancer Treatment

Fri, 17 Apr 2026 06:34:33 +0000
Intellectual Property

USPTO granted Patent US12600760B2 to The General Hospital Corporation on April 14, 2026, covering chimeric antigen receptors (CARs) targeting CD79B and CD19 for cancer treatment. The patent includes methods for producing T cells with CARs having extracellular domains that bind both CD79b and CD19. Invented by Marcela V. Maus, the patent covers upfront treatment methods where the patient has not been previously treated for the cancer.